NYSE:DTC NASDAQ:BNR ASX:LPI TSX:DXB EURONEXT:EGR ASX:VMM ASX:DCN NYSE:STK NYSE:BIT TSX:KRR
Momentum leading shares are the market's best performers today. They are the fastest-growing shares on the ASX over the last 90 days. These companies can't get to be leaders without first appearing on our Launch Pad list.
The Launch Pad List is published...
ASX:BIT Biotron Limited is engaged in the research, development, and commercialization of drugs targeting significant viral diseases with unmet medical need. The Company has BIT225 in clinical development for HIV-1, and a promising preclinical program for HBV. In addition, Biotron has several earlier stage programs designing drugs that target a class of virus...
Watching BIOTRON closely. 2 Scenarios:
1. Break of internal trend within the symmetrical triangle will see us return to the .065-.080 region (AREA OF INTEREST).
-We've had 2 bounces on the .382 Fib region creating a double top @ .115 Equilibrium
-Break of internal uptrend trendline.
-Currently broken the center band of bollinger bands.
-We've also had a death...
$BIT- Daily, Price bounced off 50% fibs and Support, looks set to test old high at 18c...Indis are showing bullish signs...
FA wise: waiting of results of their Anti virus compounds against #coronavirus..
gave me a bit of a scare, got in too early...lol
Disc: I hold
Let's see
After a recent retracement to 0.083 as I had showed the probability of such move, BIT is hitting 0.135 this is far more than what i thought could happen that soon but my target were to go beyond 0.1. I see some rsi bearish divergence and I have taken some profit. I will wait and see if it goes up again. If it falls below 1$ I am out, the upwards momentum will be...
BIotron BIT is breaking out beautifully from a bear trend it was in for a couple of months. From the TA point of view it is standing now at 0.618 fib of the last retracement. I am waiting for it to break recent highs 0.115 to get into more positions. We may see a small retracement to the 0.085 levels before next move up.
Biotron was a big mover after announcing the establishment of an expert Scientific Advisory Board. The board is tasked with the responsibility of spearheading and overseeing the upcoming Phase 2 HIV-1 clinical development program.
Chaired By professor Robert L Murphy, the board includes an international group of experts with vast experience in matters pertaining...
Their letter to shareholders didn't come out with much fanfare, but I like the space they are operating in. Couple of things that caught my eye was their successful trial in 2018 of their HIV product and they have spent the last year analysing the data out of it and they are soon holding a Scientific/Clinical Advisory Meeting with internationally recognised HIV-1...
Having been 'oft times described as 'fashionably late' I AM VERY HAPPY to see My Projection of ASX:BIT (Biotron) follow the expected path of My Chart Projection.
After a 'STELLAR' run throughout October 2018 ('SP' up 17X ) after officially announcing their BREAKTHROUGH Drug 'BIT 225' 's Phase 2 Clinical Trial success in taking a HUGE leap towards the COMPLETE...
Recent hype has pushed this stock up exponentially given successful news of their trial to target cells to eliminate AIDS, but what goes up must come down, so expecting it to hover close to the green support line and for its RSI to drop below..
76-89 RSI expect a pullback (reliable)
36-39 RSI expect a rebound (only two indicators)
Not enough data for a strong...
